T-DM1 show overall survival advantage as Roche/Genentech make US and EU filings
This article was originally published in Scrip
Roche and its cancer specialist unit Genentech have announced that following the demonstration of an overall survival benefit in the Phase III EMILIA study, they will file for US and EU regulatory approval of the antibody-drug conjugate T-DM1 (trastuzumab emtansine). The filing had been widely expected since the antibody-drug conjugate – developed with cytotoxic and conjugation technology developed by Waltham, Massachusetts-based Immunogen - generated impressive progression-free survival results in EMILIA. Analysts are anticipating approval as early as the first quarter of 2013.
You may also be interested in...
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.